Markets:

Overview

News

Currencies

International

Treasuries

Ipsen Sa ADR (OP:IPSEY)

48.19 +3.09 (+6.86%)

Streaming Delayed Price Updated: 11:59 AM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Ipsen Sa ADR

Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing

November 10, 2023

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

November 01, 2023

Virtual Investor Conference on November 8th and 9th, 2023

From Virtual Investor Conferences

Via GlobeNewswire

Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing

May 18, 2023

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023

May 09, 2023

From Virtual Investor Conferences

Via GlobeNewswire

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023

May 15, 2023

From Virtual Investor Conferences

Via GlobeNewswire

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.

January 27, 2023

From Ipsen

Via Business Wire

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI

January 20, 2023

From Ipsen

Via Business Wire

Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases

January 09, 2023

From Ipsen

Via Business Wire

Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva

December 23, 2022

From Ipsen

Via Business Wire

Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy

December 08, 2022

From Ipsen

Via Business Wire

Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

November 09, 2022

From Ipsen

Via Business Wire

Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance

October 27, 2022

From Ipsen

Via Business Wire

Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting

October 25, 2022

From Ipsen

Via Business Wire

Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology

August 12, 2022

From Ipsen

Via Business Wire

Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022

August 05, 2022

From Ipsen

Via Business Wire

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

August 03, 2022

From Ipsen

Via Business Wire

Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic

August 01, 2022

From Ipsen

Via Business Wire

Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance

July 28, 2022

From Ipsen

Via Business Wire

Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission

June 29, 2022

From Ipsen

Via Business Wire

Ipsen to acquire Epizyme, expanding its portfolio in oncology

June 27, 2022

From Epizyme, Inc.

Via Business Wire

Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury

June 09, 2022

From Ipsen

Via Business Wire

Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer

May 26, 2022

From Ipsen

Via Business Wire

Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer

May 03, 2022

From Ipsen

Via Business Wire

Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022

April 27, 2022

From Ipsen

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.